PolyPid Ltd. (PYPD) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Polypeed first quarter 2025 conference call. At this time all participants are in a listen only mode. After the speaker's presentation there will be a question and answer session. To ask a question during this session you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Brian Ritchie. Please go ahead. Thank you all for participating in Polypeach's first quarter 2025 earnings conference call. Joining me on the call today is will be Dikla Tchotchkes-Axelbrad, Chief Executive Officer of PolyPede, Johnny Misalowan, PolyPede's Chief Financial Officer, and Ori Warshawski, Chief Operating Officer, U.S. of PolyPede. Earlier today, PolyPede released its financial results for the three months ended March 31st, 2025. A copy of the press release is available in the investor section on the company's website, www.polypeed.com. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, management is making forward-looking statements when it discusses the potential efficacy of D-Plex 100 and the probability of success of the trial, that the gross proceeds from the company's last financing extend the company's cash runway into the third quarter of 2025, beyond the expected top-line results from Shield 2, the expected timing for top-line results from the Shield 2 trial, potential NDA and MAA submissions and the timing thereof, preparations for regulatory submissions, finalization of CMC a...